B+
Bull case
25%
Probability
Target price
$4.20
+63.4% vs current
NKTX
NkartaDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-20
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
45%
Probability
Target price
$2.40
-6.6% vs current
B-
Bear case
30%
Probability
Target price
$1.30
-49.4% vs current
AI sentiment snapshot
Latest data as of 2026-06-09
Recent news sentiment (30D)
0.0
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Sentiment proxy
+42.8
Score
AI commentary
Primary-source support is strong for the quarter update, protocol amendments, and runway, but external confirmation is thin: the packet has no recent trusted-news flow, no usable social aggregate, and no analyst revision evidence. The deterministic prior remains negative, which fits a cautious monitoring stance because valuation still hinges on a single 2026 data reveal that has not yet occurred.
RankAlpha Sentiment Codex - 2026-06-09
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-06-30catalystCash runway keeps near-term financing pressure mutedMedium impact
Nkarta reported $266.7 million of cash, cash equivalents, restricted cash, and investments at March 31, 2026 and said current resources are expected to fund operations into 2029, which reduces immediate financing overhang while the company waits for efficacy data.[#SEC-8K-2026-05-12] [#10-Q-2026-05-12]
2026-09-30catalystProtocol changes may improve enrollment reach and trial practicalityHigh impact
Nkarta said it reached agreement with the FDA to allow outpatient dosing in community settings, optional re-dosing, removal of overnight monitoring, and expansion of Ntrust-2 into rheumatoid arthritis. If site activation and enrollment benefit, this could improve the odds of a more useful 2026 dataset, but execution still needs to prove out.[#SEC-8K-2026-05-12]
2026-12-31eventInitial Ntrust-1 and Ntrust-2 data are the main 2026 binaryHigh impact
Management said initial clinical data from Ntrust-1 and Ntrust-2 are planned for presentation at a medical meeting in 2026, with dosing ongoing at 4 billion cells per dose across indications. The stock still lacks human efficacy proof, so the first dataset is the central valuation driver.[#SEC-8K-2026-05-12] [#PR-EARNINGS-2026-05-13]
Recommendation
N/A
No formal recommendation provided.
As of 2026-06-09 • Updated nightlySource: Internal modelMethodology